Patents Examined by Christina Chan
  • Patent number: 7786257
    Abstract: A novel peptide sequence having the general formula AB wherein each of A and B represent a chain of amino acid residues and wherein said A chain is capable of binding with a major histocompatibility complex on an antigen presenting cell, and wherein said B chain is capable of binding with a Signal-2 receptor on an antigen presenting cell. Preferred forms of the peptide sequence further include an X chain positioned intermediate the A chain and the B chain. Moreover, preferred forms include an A chain which has at least about 10% sequence homology with a Signal-1 moiety, or is a peptidomimetic of a Signal-1 moiety, said B chain has at least 10% sequence homology with a Signal-2 receptor moiety, or is a peptidomimetic of a Signal-2 receptor moiety, and wherein the X chain has at least one amino acid residue, or is a peptidomimetic of that amino acid residue.
    Type: Grant
    Filed: December 18, 2000
    Date of Patent: August 31, 2010
    Assignee: University of Kansas
    Inventors: Joseph S. Murray, Teruna J. Siahaan, Yongbo Hu
  • Patent number: 7507404
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 2, 2002
    Date of Patent: March 24, 2009
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Colin K. Watanabe, William I. Wood
  • Patent number: 7414111
    Abstract: Methods of amplifying nucleic acid have now been discovered which include the steps of: a) annealing a primer to a template nucleic acid sequence, the primer having a first portion which anneals to the template and a second portion of predetermined sequence; b) synthesizing a polynucleotide that anneals to and is complementary to the portion of the template between the location at which the first portion of the primer anneals to the template and the end of the template, the polynucleotide having a first end and a second end, wherein the first end incorporates the primer; c) separating the polynucleotide synthesized in step (b) from the template; d) annealing a nested oligonucleotide to the second end of the polynucleotide synthesized in step (b), the nested oligonucleotide having a first portion that anneals to the second end of the polynucleotide and a second portion having the same predetermined sequence as the second portion of the primer; e) extending the polynucleotide synthesized in step (b) to provide
    Type: Grant
    Filed: December 15, 2003
    Date of Patent: August 19, 2008
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Toshiaki Maruyama, Katherine S. Bowdish, Shana Frederickson, Mark Renshaw
  • Patent number: 7399741
    Abstract: The present invention relates to the use of therapeutic compounds in the modification of T-cell, T-cell-antigen presenting cell (APC) interactions and the interactions between pathogenic organisms and immunocompetent cells of a host. In particular it relates to the use of these compounds in the modulation of the interaction between Notch proteins and their ligands and to the use of such compounds in the therapy of conditions such as graft rejection, autoimmunity, allergy, and asthma and infectious diseases.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: July 15, 2008
    Assignee: Celldex Therapeutics Limited
    Inventors: Jonathan Robert Lamb, Margaret Jane Dallman, Gerard Francis Hoyne
  • Patent number: 7399471
    Abstract: Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the FIGS. 1a to 16b. The obtained polypeptides, being Fab fragments, MAY be used directly as an active ingredient in pharmaceutical and diagnostic compositions. The Fab and their DNA sequences can also be used for the preparation of complete recombinant Anti-Rhesus D antibodies. Useful in pharmaceutical and diagnostic compositions.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: July 15, 2008
    Assignee: ZLB Behring AG
    Inventors: Andreas Morell, Martin Imboden, Beda Stadler, Sylvia Miescher, Monique Vogel, Hanspeter Amstutz
  • Patent number: 7390781
    Abstract: Disclosed are novel proteins, referred to as truncated glial cell line-derived neurotrophic factor (truncated GDNF) proteins, that promote dopamine uptake by dopaminergic cells and promote the survival of nerve cells. Also disclosed are processes for obtaining the truncated GDNF proteins by recombinant genetic engineering techniques.
    Type: Grant
    Filed: January 7, 2004
    Date of Patent: June 24, 2008
    Assignee: Amgen Inc.
    Inventor: Shaw-Fen Sylvia Hu
  • Patent number: 7390486
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 9, 2002
    Date of Patent: June 24, 2008
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
  • Patent number: 7390490
    Abstract: There are provided uses of an antibody directed to CX3CR1 and fractalkine. Killer lymphocytes can be readily identified, eliminated and separated by using an anti-CX3CR1 antibody. Further, there can be provided an antibody drug for suppressing chemotaxis and cytotoxic activity of killer lymphocytes by suppressing an interaction between CX3CR1 and fractalkine.
    Type: Grant
    Filed: September 13, 2005
    Date of Patent: June 24, 2008
    Assignee: Eisai Co., Ltd.
    Inventors: Toshio Imai, Miyuki Nishimura, Kenzo Muramoto, Yoshikazu Kuboi
  • Patent number: 7390782
    Abstract: The invention involves methods of regulating cell growth and division to control disease processes by manipulating mitochondrial metabolism and the expression of cell surface immune proteins. The invention also involves related compositions and screening assays.
    Type: Grant
    Filed: March 17, 2004
    Date of Patent: June 24, 2008
    Assignee: University of Vermont and State Agricultural College
    Inventor: Martha Karen Newell
  • Patent number: 7390877
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 9, 2002
    Date of Patent: June 24, 2008
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, Colin K. Watanabe, William I. Wood
  • Patent number: 7388072
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE tumor associated genes, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of MAGE genes.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: June 17, 2008
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Yi Zhang, Pascal Chaux, Thierry Boon-Falleur, Pierre Van Der Bruggen
  • Patent number: 7387994
    Abstract: The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or AV-malformations or aneurysms or endoleaks; the solid-phase agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the rapid formation of a platelet-mediated thrombus about the solid-phase agent causing vessel occlusion.
    Type: Grant
    Filed: August 17, 2005
    Date of Patent: June 17, 2008
    Assignee: ViRexx Medcial Corp.
    Inventors: Michael W. Stewart, Antoine Noujaim, Roland H. Person
  • Patent number: 7385044
    Abstract: Peptides which have an amino acid sequence identical to sequences found in tumor rejection antigen precursors, such as NY-ESO-1, and SSX-2, are disclosed. These peptides bind to MHC-Class II molecules, such as HLA-DR molecules, and provoke proliferation of CD4+ cells.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: June 10, 2008
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ozlem Tureci, Ugur Sahin, Michael Pfreundschuh
  • Patent number: 7381800
    Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.
    Type: Grant
    Filed: June 24, 2004
    Date of Patent: June 3, 2008
    Assignee: Human Genome Sciences, Inc.
    Inventors: Yanggu Shi, Paul E. Young, Reinhard Ebner, Daniel R. Soppet, Steven M. Ruben
  • Patent number: 7381413
    Abstract: The invention involves methods of regulating cell growth and division to control disease processes by manipulating mitochondrial metabolism and the expression of cell surface immune proteins. The invention also involves related compositions and screening assays.
    Type: Grant
    Filed: March 27, 1999
    Date of Patent: June 3, 2008
    Assignee: University of Vermont and State Agricultural College
    Inventor: Martha Karen Newell
  • Patent number: 7378491
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 2, 2002
    Date of Patent: May 27, 2008
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Colin K. Watanabe, William I. Wood
  • Patent number: 7378097
    Abstract: A transcutaneous immunization system where the topical application of an adjuvant and an antigen or nucleic acid encoding for an antigen, to intact skin induces a systemic or mucosol antibody response. The immune response so elicited can be enhanced by physical or chemical skin penetration enhancement.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: May 27, 2008
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Gregory M. Glenn, Carl R. Alving
  • Patent number: 7374762
    Abstract: The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: May 20, 2008
    Assignee: ImmunoGen, Inc.
    Inventors: Godfrey Amphlett, Wei Zhang, Michael Fleming
  • Patent number: 7371845
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.
    Type: Grant
    Filed: May 23, 2006
    Date of Patent: May 13, 2008
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Yi Zhang, Pascal Chaux, Thierry Boon-Falleur, Pierre Van Der Bruggen
  • Patent number: 7371383
    Abstract: The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: May 13, 2008
    Assignees: MedImmune, Inc., Ludwig Institute for Cancer Research
    Inventors: Jennifer Lynne Reed, William Dall'Acqua, Jacques Van Snick, Jean-Christophe Renauld, Francoise Cormont, Catherine Uyttenhove